127 related articles for article (PubMed ID: 33879555)
1. PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies.
Sheng Q; D'Alessio JA; Menezes DL; Karim C; Tang Y; Tam A; Clark S; Ying C; Connor A; Mansfield KG; Rondeau JM; Ghoddusi M; Geyer FC; Gu J; McLaughlin ME; Newcombe R; Elliot G; Tschantz WR; Lehmann S; Fanton CP; Miller K; Huber T; Rendahl KG; Jeffry U; Pryer NK; Lees E; Kwon P; Abraham JA; Damiano JS; Abrams TJ
Mol Cancer Ther; 2021 Jul; 20(7):1270-1282. PubMed ID: 33879555
[TBL] [Abstract][Full Text] [Related]
2. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
Kinneer K; Meekin J; Tiberghien AC; Tai YT; Phipps S; Kiefer CM; Rebelatto MC; Dimasi N; Moriarty A; Papadopoulos KP; Sridhar S; Gregson SJ; Wick MJ; Masterson L; Anderson KC; Herbst R; Howard PW; Tice DA
Clin Cancer Res; 2018 Dec; 24(24):6570-6582. PubMed ID: 30131388
[TBL] [Abstract][Full Text] [Related]
3. A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors.
Duca M; Lim DW; Subbiah V; Takahashi S; Sarantopoulos J; Varga A; D'Alessio JA; Abrams T; Sheng Q; Tan EY; Rosa MS; Gonzalez-Maffe J; Sand-Dejmek J; Fabre C; Martin M
Mol Cancer Ther; 2022 Apr; 21(4):625-634. PubMed ID: 35131875
[TBL] [Abstract][Full Text] [Related]
4. RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models.
Strop P; Tran TT; Dorywalska M; Delaria K; Dushin R; Wong OK; Ho WH; Zhou D; Wu A; Kraynov E; Aschenbrenner L; Han B; O'Donnell CJ; Pons J; Rajpal A; Shelton DL; Liu SH
Mol Cancer Ther; 2016 Nov; 15(11):2698-2708. PubMed ID: 27582525
[TBL] [Abstract][Full Text] [Related]
5. Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer.
Cho S; Zammarchi F; Williams DG; Havenith CEG; Monks NR; Tyrer P; D'Hooge F; Fleming R; Vashisht K; Dimasi N; Bertelli F; Corbett S; Adams L; Reinert HW; Dissanayake S; Britten CE; King W; Dacosta K; Tammali R; Schifferli K; Strout P; Korade M; Masson Hinrichs MJ; Chivers S; Corey E; Liu H; Kim S; Bander NH; Howard PW; Hartley JA; Coats S; Tice DA; Herbst R; van Berkel PH
Mol Cancer Ther; 2018 Oct; 17(10):2176-2186. PubMed ID: 30065100
[TBL] [Abstract][Full Text] [Related]
6. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
[TBL] [Abstract][Full Text] [Related]
7. Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer.
Scribner JA; Brown JG; Son T; Chiechi M; Li P; Sharma S; Li H; De Costa A; Li Y; Chen Y; Easton A; Yee-Toy NC; Chen FZ; Gorlatov S; Barat B; Huang L; Wolff CR; Hooley J; Hotaling TE; Gaynutdinov T; Ciccarone V; Tamura J; Koenig S; Moore PA; Bonvini E; Loo D
Mol Cancer Ther; 2020 Nov; 19(11):2235-2244. PubMed ID: 32967924
[TBL] [Abstract][Full Text] [Related]
8. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.
Huhe M; Lou J; Zhu Y; Zhao Y; Shi Y; Wang B; Sun X; Zhang X; Zhang Y; Chen ZN
Biochem Biophys Res Commun; 2019 Jun; 513(4):1083-1091. PubMed ID: 31010682
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Efficacy and Safety Assessment of an Antibody-Drug Conjugate Targeting the c-RET Proto-Oncogene for Breast Carcinoma.
Nguyen M; Miyakawa S; Kato J; Mori T; Arai T; Armanini M; Gelmon K; Yerushalmi R; Leung S; Gao D; Landes G; Haak-Frendscho M; Elias K; Simmons AD
Clin Cancer Res; 2015 Dec; 21(24):5552-62. PubMed ID: 26240273
[TBL] [Abstract][Full Text] [Related]
10. Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma.
Tao Y; Wang R; Lai Q; Wu M; Wang Y; Jiang X; Zeng L; Zhou S; Li Z; Yang T; Yao Y; Wu Y; Yu L; Fu Y; Lai W; Peng Y; Lu Y; Zhang Z; Guo C; Zhang G; Gou L; Yang J
Mol Oncol; 2019 Sep; 13(9):1855-1873. PubMed ID: 31116512
[TBL] [Abstract][Full Text] [Related]
11. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Characterization of the Radioimmunoconjugate
Funase Y; Nakamura E; Kajita M; Saito Y; Oshikiri S; Kitano M; Tokura M; Hino A; Uehara T
J Nucl Med; 2021 Feb; 62(2):232-239. PubMed ID: 32737245
[TBL] [Abstract][Full Text] [Related]
13. ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer.
Barok M; Le Joncour V; Martins A; Isola J; Salmikangas M; Laakkonen P; Joensuu H
Cancer Lett; 2020 Mar; 473():156-163. PubMed ID: 31904483
[TBL] [Abstract][Full Text] [Related]
14. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Ogitani Y; Aida T; Hagihara K; Yamaguchi J; Ishii C; Harada N; Soma M; Okamoto H; Oitate M; Arakawa S; Hirai T; Atsumi R; Nakada T; Hayakawa I; Abe Y; Agatsuma T
Clin Cancer Res; 2016 Oct; 22(20):5097-5108. PubMed ID: 27026201
[TBL] [Abstract][Full Text] [Related]
15. Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.
He K; Xu J; Liang J; Jiang J; Tang M; Ye X; Zhang Z; Zhang L; Fu B; Li Y; Bai C; Zhang L; Tao W
Mol Cancer Ther; 2019 Jun; 18(6):1104-1114. PubMed ID: 30962319
[TBL] [Abstract][Full Text] [Related]
16. A Novel HER3-Targeting Antibody-Drug Conjugate, U3-1402, Exhibits Potent Therapeutic Efficacy through the Delivery of Cytotoxic Payload by Efficient Internalization.
Hashimoto Y; Koyama K; Kamai Y; Hirotani K; Ogitani Y; Zembutsu A; Abe M; Kaneda Y; Maeda N; Shiose Y; Iguchi T; Ishizaka T; Karibe T; Hayakawa I; Morita K; Nakada T; Nomura T; Wakita K; Kagari T; Abe Y; Murakami M; Ueno S; Agatsuma T
Clin Cancer Res; 2019 Dec; 25(23):7151-7161. PubMed ID: 31471314
[TBL] [Abstract][Full Text] [Related]
17. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
[TBL] [Abstract][Full Text] [Related]
18. Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models.
Challita-Eid PM; Satpayev D; Yang P; An Z; Morrison K; Shostak Y; Raitano A; Nadell R; Liu W; Lortie DR; Capo L; Verlinsky A; Leavitt M; Malik F; Aviña H; Guevara CI; Dinh N; Karki S; Anand BS; Pereira DS; Joseph IB; Doñate F; Morrison K; Stover DR
Cancer Res; 2016 May; 76(10):3003-13. PubMed ID: 27013195
[TBL] [Abstract][Full Text] [Related]
19. A Novel, Fully Human Anti-fucosyl-GM1 Antibody Demonstrates Potent
Ponath P; Menezes D; Pan C; Chen B; Oyasu M; Strachan D; LeBlanc H; Sun H; Wang XT; Rangan VS; Deshpande S; Cristea S; Park KS; Sage J; Cardarelli PM
Clin Cancer Res; 2018 Oct; 24(20):5178-5189. PubMed ID: 30021910
[No Abstract] [Full Text] [Related]
20. Exposure-Efficacy Analysis of Antibody-Drug Conjugates Delivering an Excessive Level of Payload to Tissues.
Zhang D; Dragovich PS; Yu SF; Ma Y; Pillow TH; Sadowsky JD; Su D; Wang W; Polson A; Khojasteh SC; Hop CECA
Drug Metab Dispos; 2019 Oct; 47(10):1146-1155. PubMed ID: 31358513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
